These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 21349419)
21. Divergent role of (68)Ga-labeled somatostatin analogs in the workup of patients with NETs: AIIMS experience. Naswa N; Bal CS Recent Results Cancer Res; 2013; 194():321-51. PubMed ID: 22918767 [TBL] [Abstract][Full Text] [Related]
22. [The scintigraphy of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors]. Chiti A; Spinelli A; Bombardieri E Radiol Med; 1997 Oct; 94(4):362-70. PubMed ID: 9465244 [No Abstract] [Full Text] [Related]
23. Somatostatin receptor imaging with (111)In-pentetreotide in gastro-intestinal tract and lung neuroendocrine tumors-Impact on targeted treatment. Gerasimou G; Moralidis E; Gotzamani-Psarrakou A Hell J Nucl Med; 2010; 13(2):158-62. PubMed ID: 20808990 [TBL] [Abstract][Full Text] [Related]
24. Nephrotoxicity/renal failure after therapy with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review. Stolniceanu CR; Nistor I; Bilha SC; Constantin V; Simona V; Matovic M; Stefanescu C; Covic A Nucl Med Commun; 2020 Jul; 41(7):601-617. PubMed ID: 32404645 [TBL] [Abstract][Full Text] [Related]
26. [Imaging of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors]. Mure A; Lebtahi R; de Labriolle-Vaylet C; Askienazy S Gastroenterol Clin Biol; 1998 Oct; 22(10):809-18. PubMed ID: 9854206 [No Abstract] [Full Text] [Related]
27. Therapy: Neuroendocrine cancer--are two radionuclides better than one? Kwekkeboom DJ Nat Rev Endocrinol; 2012 May; 8(6):326-8. PubMed ID: 22547261 [No Abstract] [Full Text] [Related]
28. [Somatostatin receptor-based imaging and therapy of digestive endocrine tumors]. Illouz F; Sadoul JL; Rohmer V Ann Endocrinol (Paris); 2010 Sep; 71 Suppl 1():S3-12. PubMed ID: 21237328 [TBL] [Abstract][Full Text] [Related]
29. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues. De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786 [TBL] [Abstract][Full Text] [Related]
30. [Scintigraphy of somatostatin receptors in the diagnosis and staging of neuroendocrine tumors of the digestive tract and pancreas]. Banzo J; Abós MD; Prats E; García F; Razola P Rev Esp Med Nucl; 2000 Jun; 19(3):225-41. PubMed ID: 11062088 [No Abstract] [Full Text] [Related]
31. [Significance of false-positive findings of somatostatin receptor scintigraphy in diagnosis of neuroendocrine tumors of the gastroenteropancreatic system]. Faiss S; Scherübl H; Bäder M; Fett U; Koppenhagen K; Wiedenmann B; Riecken EO Z Gastroenterol; 1994 May; 32(5):243-6. PubMed ID: 7915450 [TBL] [Abstract][Full Text] [Related]
33. 68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETs. Werner RA; Bluemel C; Allen-Auerbach MS; Higuchi T; Herrmann K Ann Nucl Med; 2015 Jan; 29(1):1-7. PubMed ID: 25139472 [TBL] [Abstract][Full Text] [Related]
34. Altered biodistribution of somatostatin analogues after first cycle of Peptide receptor radionuclide therapy. Van Binnebeek S; Deroose CM; Baete K; Terwinghe C; Vanbilloen B; Koole M; Haustermans K; Mortelmans L; Verslype C; Van Cutsem E; Verbruggen A; Mottaghy FM J Clin Oncol; 2011 Jul; 29(19):e579-81. PubMed ID: 21555687 [No Abstract] [Full Text] [Related]
35. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Kwekkeboom DJ; Krenning EP; Lebtahi R; Komminoth P; Kos-Kudła B; de Herder WW; Plöckinger U; ; Neuroendocrinology; 2009; 90(2):220-6. PubMed ID: 19713714 [TBL] [Abstract][Full Text] [Related]
36. Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours. Forrer F; Mueller-Brand J; Maecke H Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):511-2; author reply 513. PubMed ID: 15688195 [No Abstract] [Full Text] [Related]
37. [Gastroenteropancreatic neuroendocrine tumors: diagnosis and therapy in nuclear medicine]. Haug AR; Bartenstein P Internist (Berl); 2012 Feb; 53(2):161-6. PubMed ID: 22231696 [TBL] [Abstract][Full Text] [Related]
38. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. Toumpanakis C; Caplin ME Semin Oncol; 2013 Feb; 40(1):56-68. PubMed ID: 23391113 [TBL] [Abstract][Full Text] [Related]
39. [Diagnostics and treatment of neuroendocrine tumors of the digestive tract in the light of the present standards]. Szczeblowska D Pol Merkur Lekarski; 2007 May; 22(131):437-41. PubMed ID: 17679390 [TBL] [Abstract][Full Text] [Related]
40. In situ radiotherapy with 111In-pentetreotide. State of the art and perspectives. McCarthy KE; Woltering EA; Anthony LB Q J Nucl Med; 2000 Mar; 44(1):88-95. PubMed ID: 10932605 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]